Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Summit's Antibiotic Spares The Microbiome And Spoils The C Diff Rods

This article was originally published in Scrip

Executive Summary

Summit Therapeutics' novel narrow-spectrum antibiotic ridinilazole (SMT19969) is highly effective in reducing recurrence in Clostridium difficile infections (CDI), and could address a major unmet need in the treatment of the disease, suggest Phase II data due to be presented at the ECCMID meeting in Amsterdam in April.

Advertisement

Related Content

Merck & Co Expands C Diff Franchise With US Zinplava Approval

Topics

Advertisement
UsernamePublicRestriction

Register